| OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD (NCT07450820) | AstraZeneca | 2026-02-18 |
| A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food (NCT07404137) | AstraZeneca | 2026-02-16 |
| A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144 (NCT07518459) | AstraZeneca | 2026-02-11 |
| A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. (NCT07215702) | AstraZeneca | 2026-02-10 |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 (NCT07431281) | AstraZeneca | 2026-02-03 |
| Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (NCT06531798) | AstraZeneca | 2026-01-30 |
| Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab (NCT07363642) | AstraZeneca | 2026-01-28 |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs (NCT07336446) | AstraZeneca | 2026-01-27 |
| Anifrolumab Malignancy and Serious Infections Study (NCT07000110) | AstraZeneca | 2026-01-26 |
| Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT07402915) | AstraZeneca | 2026-01-26 |
| A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (NCT07312851) | AstraZeneca | 2026-01-19 |
| Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (NCT06594068) | AstraZeneca | 2026-01-16 |
| A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus (NCT07433062) | AstraZeneca | 2026-01-14 |
| A Study of AZD0120 in Autoimmune Diseases (NCT07295847) | AstraZeneca | 2026-01-09 |
| Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (NCT07155226) | AstraZeneca | 2026-01-09 |
| A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment (NCT07343960) | AstraZeneca | 2026-01-06 |
| Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. (NCT07330245) | AstraZeneca | 2025-12-31 |
| Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus (NCT07288515) | AstraZeneca | 2025-12-31 |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (NCT07218809) | AstraZeneca | 2025-12-29 |
| The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia (NCT07390240) | AstraZeneca | 2025-12-29 |
| Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis (NCT07245576) | AstraZeneca | 2025-12-26 |
| ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia (NCT07399665) | AstraZeneca | 2025-12-25 |
| Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia (NCT07247292) | AstraZeneca | 2025-12-23 |
| Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia (NCT07247279) | AstraZeneca | 2025-12-23 |
| A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy (NCT07214753) | AstraZeneca | 2025-12-20 |
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis (NCT07276581) | AstraZeneca | 2025-12-15 |
| Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo (NCT07069829) | AstraZeneca | 2025-12-15 |
| Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody (NCT07285213) | AstraZeneca | 2025-12-10 |
| Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease (NCT06851806) | AstraZeneca | 2025-12-10 |
| A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants (NCT07290283) | AstraZeneca | 2025-12-10 |
| An Open-label Study of AZD0120 in Adults With Multiple Sclerosis (NCT07224373) | AstraZeneca | 2025-12-09 |
| A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (NCT07222917) | AstraZeneca | 2025-12-05 |
| Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants (NCT07201558) | AstraZeneca | 2025-12-02 |
| A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy (NCT07241104) | AstraZeneca | 2025-12-01 |
| The Eplontersen Pregnancy and Lactation Outcomes Study (NCT07205666) | AstraZeneca | 2025-11-30 |
| Study of Patient With Frequent Exacerbations in Moscow (NCT07307781) | AstraZeneca | 2025-11-28 |
| The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management (NCT06909773) | AstraZeneca | 2025-11-28 |
| A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (NCT07161414) | AstraZeneca | 2025-11-25 |
| DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns (NCT07109154) | AstraZeneca | 2025-11-25 |
| A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (NCT06996782) | AstraZeneca | 2025-11-24 |
| A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (NCT07073950) | AstraZeneca | 2025-11-24 |
| Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy) (NCT07221331) | AstraZeneca | 2025-11-19 |
| Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China (NCT07161388) | AstraZeneca | 2025-11-17 |
| A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia (NCT07218900) | AstraZeneca | 2025-11-13 |
| Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (NCT07109219) | AstraZeneca | 2025-11-12 |
| A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 (NCT07220954) | AstraZeneca | 2025-11-11 |
| AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (NCT07215585) | AstraZeneca | 2025-11-11 |
| Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease (NCT07228364) | AstraZeneca | 2025-11-10 |
| A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years (NCT07216131) | AstraZeneca | 2025-11-10 |
| The Anifrolumab PRIM Program (NCT06795893) | AstraZeneca | 2025-11-07 |
| A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization (NCT07088926) | AstraZeneca | 2025-11-06 |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (NCT07291037) | AstraZeneca | 2025-10-31 |
| Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation (NCT07414134) | AstraZeneca | 2025-10-31 |
| A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer (NCT07205822) | AstraZeneca | 2025-10-30 |
| Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes (NCT07215026) | AstraZeneca | 2025-10-27 |
| A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE (NCT07245407) | AstraZeneca | 2025-10-27 |
| Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer (NCT06827132) | AstraZeneca | 2025-10-25 |
| The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt (NCT07218536) | AstraZeneca | 2025-10-13 |
| Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics (NCT07315958) | AstraZeneca | 2025-10-08 |
| Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer (NCT07181161) | AstraZeneca | 2025-10-01 |
| A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer (NCT07192614) | AstraZeneca | 2025-09-30 |
| A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT07123454) | AstraZeneca | 2025-09-24 |
| Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance (NCT06995833) | AstraZeneca | 2025-09-19 |
| Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology (NCT07167433) | AstraZeneca | 2025-09-19 |
| DESTINY-PANTUMOUR04 (NCT07124000) | AstraZeneca | 2025-09-18 |
| LTFU for All Cell and Gene Therapy Studies (NCT06194461) | AstraZeneca | 2025-09-17 |
| Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. (NCT06992609) | AstraZeneca | 2025-09-15 |
| Tezspire Cardiac Events PASS (NCT06951867) | AstraZeneca | 2025-09-15 |
| A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain (NCT07029737) | AstraZeneca | 2025-09-05 |
| A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) (NCT07128615) | AstraZeneca | 2025-09-04 |
| A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer (NCT07060365) | AstraZeneca | 2025-09-02 |
| Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt (NCT07144514) | AstraZeneca | 2025-08-31 |
| EXACOS EG Population (NCT06983340) | AstraZeneca | 2025-08-30 |
| A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 (NCT07143604) | AstraZeneca | 2025-08-29 |
| A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients (NCT07101874) | AstraZeneca | 2025-08-22 |
| LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada (NCT07143110) | AstraZeneca | 2025-08-20 |
| Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer (NCT07070128) | AstraZeneca | 2025-08-20 |
| Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) (NCT07154901) | AstraZeneca | 2025-08-18 |
| A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (NCT07098338) | AstraZeneca | 2025-08-07 |
| A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism (NCT07007793) | AstraZeneca | 2025-08-07 |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (NCT06952803) | AstraZeneca | 2025-08-06 |
| Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma (NCT07081633) | AstraZeneca | 2025-08-05 |
| Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant (NCT07008963) | AstraZeneca | 2025-07-31 |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (NCT07115043) | AstraZeneca | 2025-07-29 |
| A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants (NCT07088913) | AstraZeneca | 2025-07-28 |
| A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region (NCT07065344) | AstraZeneca | 2025-07-23 |
| A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (NCT07069712) | AstraZeneca | 2025-07-17 |
| This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab (NCT06862206) | AstraZeneca | 2025-07-11 |
| GRANITE: Airsupra Effectiveness in the Real World (NCT07141277) | AstraZeneca | 2025-07-09 |
| Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib. (NCT07213076) | AstraZeneca | 2025-07-04 |
| Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users (NCT06659029) | AstraZeneca | 2025-07-01 |
| TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation (NCT07038928) | AstraZeneca | 2025-06-30 |
| Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation (NCT07146113) | AstraZeneca | 2025-06-30 |
| A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT06839872) | AstraZeneca | 2025-06-30 |
| Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration (NCT07052578) | AstraZeneca | 2025-06-30 |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (NCT07082738) | AstraZeneca | 2025-06-27 |
| Hyperkalemia Quality Improvement Program (HK-QIP) Study (NCT06884267) | AstraZeneca | 2025-06-25 |
| Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy (NCT06948396) | AstraZeneca | 2025-06-25 |
| An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation (NCT07041606) | AstraZeneca | 2025-06-24 |
| Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain (NCT07013760) | AstraZeneca | 2025-06-23 |